New drugs in non-small cell lung cancer. An overview.
Chemotherapy is rather ineffective in non-small cell lung cancer. However, in the last few years, a number of new anticancer agents have been developed which have definite activity in this disease. Among them are the taxanes and CPT-11, drugs with novel mechanisms of action, new antimetabolites (edatrexate and gemcitabine), and a new vinca alkaloid (vinorelbine). Furthermore, in the near future, the better understanding of lung cancer biology will help in devising new treatment strategies.
Giaccone
G
G
Free University Hospital, Department of Oncology, Amsterdam, The Netherlands.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077143:Docetaxel; D015195:Drug Design; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D000077143:Docetaxel; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine